Involution of the rat ventral prostate and concomitant modulation of gene expression post-castration is a welldocumented phenomenon. While the rat castration model has been extensively used to study androgen regulation of gene expression in the ventral prostate, it is not clear whether all the gene expression changes post-castration are due to androgen depletion alone. To obtain insights into this, we performed differential display reverse transcriptase polymerase chain reaction (DD-RT-PCR) which resulted in the identifi cation of castration and/or fl utamide-regulated genes in the rat ventral prostate. These include clusterin, methionine adenosyl transferase IIα, and prostate-specifi c transcripts such as PBPC1BS, S100RVP and A7. While clusterin, PBPC1BS and methionine adenosyl transferase IIα are regulated by both castration and fl utamide, S100 RVP and A7 are regulated by castration alone. Interestingly, we show that fl utamide, unlike castration, does not induce apoptosis in the rat ventral prostate epithelium, which could be an underlying cause for the differential effects of castration and fl utamide treatment. We propose that castration leads to enrichment and depletion of stromal and epithelial cell types, respectively, resulting in erroneous conclusions on some of the cell type-specifi c transcripts as being androgen regulated.
Introduction
Androgens play an important role in the development, growth and maintenance of differentiated functions of the prostate. Much of the current understanding of the role of androgens in the tissue homeostasis of the prostate is based on studies on the rat ventral prostate (RVP) following castration. Lee et al (1990) demonstrated that the adult RVP is a dynamic system in which cell death in the proximal epithelium balances out cell proliferation in the distal epithelium. Castration of adult male rats leads to a rapid reduction in serum androgens, and a collapse of this dynamic equilibrium results in rapid involution and loss of secretory activity of the ventral prostate. The process of involution is an active one involving a cascade of biochemical steps leading to programmed cell death of the glandular epithelial cells (Kerr and Searle 1973; Sandford et al 1984; Kyprianou and Isaacs 1988; English et al 1989) . The glandular epithelial cells constitute about 85% of the RVP. By day 7 post-castration, loss of 70% of the glandular epithelial cells has been demonstrated (Kyprianou and Isaacs 1988; English et al 1989) . These effects of castration on the RVP can be reversed by androgen supplementation, which leads to regrowth of the prostate and restoration of secretory activity (Coffey et al 1968; Wright et al 1999) . Castration-induced programmed cell death in the RVP is accompanied by modulation of gene expression, which is also reversed by androgen supplementation. Thus, castration has been extensively used as a tool to study in vivo gene expression changes in the context of regression/ regrowth of the prostate and identifi cation of androgenChanges in gene expression following androgen receptor blockade is not equivalent to androgen ablation by castration in the rat ventral prostate regulated genes, which are of relevance for understanding (i) androgen-dependent and -independent growth of prostate cancer, and (ii) identifi cation of diagnostic/prognostic and therapeutic targets for prostate cancer.
Till date, a plethora of androgen-regulated genes have been identifi ed in the RVP using the castration model. However, very few studies have used fl utamide as a tool to probe into androgen-regulated gene expression in the prostate. Although it is expected that castration and fl utamide will exert similar effects on gene expression and physiology of the prostate, a few reports contrary to this have been published recently. Flutamide does not induce TRPM-2 mRNA (a testosterone-repressed transcript) in the RVP (Russo et al 1994) . Conversely, Turner et al (2001) reported the inability of fl utamide to block suppression of TRPM-2 by testosterone. However, in an independent study, Leger et al (1988) demonstrated induction of TRPM-2 following fl utamide treatment in castrated rats receiving a maintenance dose of androgen. Castration and fl utamide administration have been shown to have opposite effects on the expression of protein kinase C (PKC) isoforms in the RVP. While castration leads to reduced expression, fl utamide has been shown to increase the levels of PKC isoforms (Montalvo et al 2002) . In our laboratory, we had previously identifi ed a few fl utamide-regulated transcripts in the RVP. Interestingly, we found that castration had a similar or no effect on the expression of the fl utamide-regulated transcripts (Limaye et al 2007) , thus reiterating the disparity in the effects of castration and fl utamide treatment as reported by other investigators. These intriguing observations warrant further investigation into the effects of castration and fl utamide on gene expression, as they may provide useful insights into the androgen regulation of gene expression in the RVP.
Here, we present further insights into the differential effects of castration and fl utamide treatment in the RVP. We analysed the effect of castration and fl utamide treatment on expression levels of a few known and unknown transcripts identifi ed by differential display reverse transcriptase polymerase chain reaction (DD-RT-PCR). Furthermore, we show that fl utamide does not induce apoptosis of the RVP epithelium. Our data suggest that the observed regulation of genes following castration could be due in part to depletion of the epithelial compartment and not due to androgen regulation. This study clearly highlights the caveat in using the castration model as a means to identify androgenregulated genes.
Methods

Animals
Wistar male rats used in this study were obtained from the Central Animal Facility at the Indian Institute of Science.
The animals were 60-70 days old and maintained according to the guidelines of the institute with access to rat chow and water ad libitum.
Hormonal manipulations
Castrations were performed via the scrotal route under ether anaesthesia and the animals were maintained for 1 day (day 1 post-castration), 3 days (day 3 post-castration) and 5 days (day 5 post-castration). Sham-castrated animals maintained for 5 days (day 5 sham-castrated) served as controls. The castrated animals receiving testosterone replacement were given three intraperitoneal injections of testosterone propionate (1 mg/kg body weight) after day 2, day 3 and day 4 post-castration. Flutamide was administered intraperitoneally in doses of 50 mg/kg body weight every 12 h for 5 days (day 5 fl utamide). In experiments to study the effect of fl utamide treatment on testosterone replacement, 5 doses of fl utamide as mentioned above were administered to testosterone-replaced rats, each given every 12 h, starting from 12 h after the fi rst testosterone propionate injection (testosterone-replaced + fl utamide-treated). In these experiments, castrated rats also received similar doses of fl utamide at identical time points (day 5 castrated + fl utamide-treated).
RNA extraction
RNA was extracted from frozen tissues using TRI Reagent (Sigma-Aldrich, USA) according to the manufacturer's instructions. The total RNA was further purifi ed using the RNeasy Kit (Qiagen, GmbH, Germany). RNA concentration was estimated by measuring the absorbance at 260 nm and the quality was assessed by agarose-formaldehyde gel electrophoresis.
DD-RT-PCR
The DD-RT-PCR protocol described by Wan and Erlander (1997) was used with minor modifi cations. Briefl y, 500 ng of total RNA was reverse transcribed with anchored primer (table 1). The resultant cDNAs were diluted 20 times in water and 1 μl was used for PCR using 500 ng of anchored primer (corresponding primer used for cDNA synthesis) and 500 ng of arbitrary primer (table 2) in the presence of α-32 P dCTP. The PCR conditions were 94°C for 20 s, 42°C for 20 s and 72°C for 30 s for 40 cycles. Of the PCR product, 1 μl was mixed with 1 μl of sequencing loading dye (95% formamide, 10 mM EDTA, 0.1% xylene cyanol and 0.1% bromophenol blue), heated at 80 O C for 5 min, chilled on ice and resolved on a 6% polyacrylamide gel containing 7 M urea, transferred onto 3 M Whatman paper (3 MM CHR), dried under vacuum at 80°C and exposed to an X-ray fi lm. Differentially expressed cDNAs were excised from the gel and eluted in 100 μl of water by boiling for 15 min. Following centrifugation at 10 000 rpm for 5 min, the cDNA in the supernatant was amplifi ed using the appropriate combination of anchored and arbitrary primers. The amplifi ed cDNAs were cloned in pBluescript or pGEMTEasy vector prior to sequencing or sequenced directly using arbitrary primers with an automated sequencer (ABI).
Northern blot analysis
cDNAs were labelled with α-32 P dCTP (specifi c activity 3000 Ci/mmol, Perkin Elmer) using the Random Primer Labeling Kit (Bangalore Genei, India) and purifi ed using Sephadex-G50 spin columns. Fifteen to 20 μg of RNA was resolved on 1% agarose-formaldehyde gel and blotted onto a nylon membrane (Biodyne ® B Membrane, Pall Corporation). The prehybridization, hybridization and washing steps were performed as described previously (Desai and Kondaiah 2000) . For quantifi cation of northern blots, the band intensities obtained for the various cDNAs were normalized against those obtained for 18S rRNA. The normalized values obtained for day 5 sham-castrated controls were assigned the value of 1 or 100, and those obtained for other treatments were plotted as fold induction or percentage of control. The quantifi cations have been graphically represented where bars represent mean ± SD. Data obtained from two animals, each from independent experiments, were used to calculate the mean and SD.
Tissue fi xation and sectioning
Ventral prostates were fi xed in 4% paraformaldehyde for a period of 48 h. The fi xed tissues were washed thoroughly with water and gradually dehydrated, cleared and paraffi n embedded using the standard protocol in an automated tissue processor TP1020 (Leica, Nussloch, Germany). Sections of 5-7 μm were cut and placed on glass slides. These were stored at 4 O C until used for TUNEL assay and in situ hybridization analysis.
TUNEL assay
Sections were deparaffi nized and rehydrated using a standard procedure. Endogenous peroxidase activity was blocked by incubating the slides in 0.6% hydrogen peroxide followed by treatment with 20 μg/ml proteinase K for 30 min at 37 O C. The slides were then incubated in 100 mM glycine in phosphate buffered saline (PBS) for 10 min followed by PBS washes (3 times for 5 min each). Sections were then equilibrated with TdT reaction buffer for 20 min at 37 O C followed by incubation for 90 min in TdT reaction buffer containing 10 μm dATP, 5 μM of biotin-16-dUTP and 8 units of TdT per section. The slides were washed in 1X SSC at room temperature for 15 min followed by washes in PBS (3 times for 5 min each). The sections were blocked with 0.2% blocking reagent (Boehringer Mannheim) and 0.05% Tween-20 in PBS for 30 min. Sections were then treated with streptavidin-peroxidase conjugate (Bangalore Genei, 1:250 dilution) in blocking reagent for 2 h. The excess conjugate was washed with PBS (3 times for 5 min each). Subsequently, the sections were exposed to 0.05% diaminobenzidine and 0.1% hydrogen peroxide in PBS until brown staining appeared. The sections were counterstained with methylene blue and mounted with 50% glycerol and observed under the microscope for the presence of TUNELpositive cells.
In situ hybridization
S100RVP cDNA was cloned in pBluescript (Stratagene) such that T7 and T3 polymerases generated the sense and antisense RNA, respectively. The plasmid was linearized with HindIII or XbaI, purifi ed and used as a template in separate reactions for in vitro transcription with T7 and T3 RNA polymerases, respectively, using DIG-RNA labelling mix (Roche).
Deparaffi nized and hydrated tissue sections were treated with 0.2 M HCl for 10 min and washed thrice in PBS for 
Sequence in bold italics is the EcoRI restriction site.
3 min each. The tissue was made permeable with 0.3% Triton X-100 in PBS and subjected to proteinase K digestion and glycine treatment, as described in the previous section. The tissue sections were post-fi xed in neutral buffered formalin and acetylated with 0.1 M triethanolamine and 0.25% acetic anhydride for 10 min. The slides were then dipped in ice-cold 20% glacial acetic acid for 10 s and immediately washed with deionized water for 5 min. The sections were dehydrated in increasing grades of ethanol (50%, 70% and absolute ethanol). The sections were prehybridized for 30 min in hybridization buffer (6X SSC, 3% SDS and 50% deionized formamide containing 100 μg/ml yeast t-RNA) in a humidifi ed chamber equilibrated with 50% formamide and maintained at 55°C. The hybridization mixture containing DIG-labelled riboprobe in hybridization buffer was heated to 80 O C for 5 min, placed on the sections (2-5 ng of riboprobe per section), covered with glass cover slips and the slides were immediately transferred to the humidifi ed chamber maintained at 55°C. Hybridization was carried out for 18 h.
After the hybridization, the cover slips were removed in 2X SSC and the slides were washed with 1X SSC/ 0.1% SDS twice for 5 min each. This was followed by two high-stringency washes at 55°C for 10 min each. The non-specifi cally bound RNA probe was digested with 10 μg/ml RNAse A in 4X SSC at 37°C for 30 min. The slides were again rinsed in 2X SSC followed by high-stringent washes with 0.2X SSC/0.1% SDS, twice for 10 min each. The sections were blocked with blocking solution containing 0.2% blocking reagent (Boehringer Mannheim) and 0.05% Tween-20 in PBS for a minimum of 2 h. The blocking solution was removed and 50 μl of alkaline phosphatase-conjugated anti-DIG Fab fragments (diluted 1: 1000 in blocking solution) was applied to each section and incubated at room temperature for 2 h. Excess antibody was washed with PBS and the sections were exposed to NBT/ BCIP substrate until specifi c staining was observed with minimum background. The reaction was stopped by dipping the slides in 10 mM Tris and 1 mM EDTA (pH 7.6), rinsed in water and counterstained with methyl green. The sections were mounted with 50% glycerol, and observed under the microscope and photographed.
Results
DD-RT-PCR
We performed DD-RT-PCR analysis of the total RNA isolated from the ventral prostates of day 5 sham-castrated, day 5 castrated and day 5 fl utamide-treated rats. Using a combination of anchored and arbitrary primers (tables 1 and 2) several differentially expressed transcripts were observed. Figure 1 shows differentially expressed transcripts along with two transcripts (A4 and A8; fi gure 1), which were not differentially expressed in castrated and fl utamide-treated RVPs. These transcripts were re-amplifi ed and either directly sequenced using the arbitrary primers or cloned into pBluescript or pGEMT-Easy vector before sequencing. Table 3 shows the identities of only the differentially regulated transcripts obtained using BLAST (Altschul et al 1990) . We could not clone the intact A7 fragment but, surprisingly, after ligation of A7 and screening for recombinants, we obtained two clones with inserts of unexpected sizes designated as A7.2 and A7.3. These were sequenced and found to contain inserts corresponding to sialic acid synthase and S100RVP, respectively. However, sequencing of the A7 PCR product and a search for identical sequences in the existing database with BLAST (Altschul et al 1990) revealed its identity to a human sequence containing MAGEE1 melanoma antigen and no similarity was found with the existing sequences in the rat database. Here we refer to this transcript as A7 mRNA. Among several novel genes, we identifi ed clusterin (a known androgen-repressed gene in RVP), which was induced upon castration and fl utamide treatment (table 3) .
Effect of castration and fl utamide treatment on clusterin and methionine adenosyl transferase IIα mRNAs
The expression of clusterin mRNA was enhanced in the RVP at day 1, day 3 and day 5 post-castration. This effect of androgen withdrawal was reversed following supplementation with testosterone propionate. Flutamide treatment also caused a substantial increase in the clusterin mRNA levels, albeit at much lower levels than with castration. A 27.43 ± 3.9-fold induction was observed on castration as compared with 10.96 ± 4.0 on fl utamide treatment (mean ± SD, N = 2, fi gure 2). In similar experiments the regulation of methionine adenosyl transferase IIα (MATIIα) was also studied. Contrary to only one transcript of MATIIα reported in the literature (Huang et al 1998) , we observed two transcripts (approximately 3.4 and 3.0 kb). The level of the higher molecular weight transcript was increased by day 3 post-castration and appeared to fall at day 5 post-castration to levels seen in sham-operated and testosterone-replaced animals. On the other hand, the low molecular weight transcript showed a gradual decrease from day 1 to day 5 post-castration, which was partially restored on testosterone replacement. Flutamide treatment enhanced the levels of the higher molecular weight transcript and moderately decreased the levels of the lower molecular weight transcript (fi gure 2). 
Effect of castration and fl utamide treatment on the prostate-specifi c PBPC1BS, A7 and S100RVP mRNA transcripts
Castration led to a dramatic fall in the steady-state expression of PBPC1BS mRNA to levels beyond detection at day 3 post-castration. Testosterone replacement restored PBPC1BS mRNA to a near-normal level (fi gure 3A). Using the A7 reamplifi ed cDNA as a radiolabelled probe, we detected a transcript of approximately 1.7 kb, which was abundantly expressed in the intact RVP. Castration led to a dramatic fall in the steady-state level of the A7 mRNA transcript, which was reversed by testosterone replacement. S100RVP also exhibited a similar pattern of regulation by castration and testosterone replacement (fi gure 3A). The kinetics of downregulation of the A7 and PBPC1BS transcripts were determined. PBPC1BS mRNA appeared to decrease more rapidly than A7. At day 1 post-castration, PBPC1BS mRNA was reduced to 18.31 ± 8.2% of the control (mean ± SD, N = 2) as opposed to 80.96 ± 18.01% in the case of A7 (mean ± SD, N = 2) (fi gure 3B). The castration data suggest that PBPC1BS, S100RVP and A7 transcripts are androgen-regulated in the RVP. In order to probe further into the regulation of these genes by androgens, the effect of fl utamide treatment on intact rats was studied. Flutamide administration caused a marked reduction in the steadystate level of PBPC1BS mRNA (fi gure 3C) . Surprisingly, the expression of A7 and S100RVP mRNAs remained unchanged upon fl utamide treatment (fi gure 3C, D). A survey of the published literature revealed that PBPC1BS
belongs to a large family of proteins called the secretoglobin family and is positioned close to RnPBPC1 and RnPBPC2 (coding for the C1 and C2 components of prostatic steroidbinding proteins, respectively) in a dendrogram showing the relatedness among members of this family (Reynolds et al 2002) . These data suggested that the expression of PBPC1BS could be prostate-specifi c. The mRNA expression of PBPC1BS by northern blot using total RNA isolated from various adult rat tissues revealed its prostate-specifi c expression (fi gure 3E). The A7 transcript was also found to be prostate-specifi c (fi gure 3E).
Effect of fl utamide on the RVP epithelium
In order to assess the apoptotic activity in the RVP following castration and fl utamide treatment, in situ detection of apoptosis (TUNEL assay) was performed. Interestingly, there was almost complete absence of TUNEL-positive nuclei in ventral prostate sections of fl utamide-treated rats (fi gure 4). In contrast, ventral prostate sections of castrated rats showed TUNEL-positive nuclei. This suggests that fl utamide does not induce apoptosis in the RVP.
mRNA in situ hybridization analysis of S100RVP
Downregulation of the S100RVP and A7 transcripts by castration but not by fl utamide, coupled with the absence of apoptotic activity following fl utamide treatment, suggested that the regulation of these mRNAs could only be apparent due to depletion of the majority of prostate epithelial cells at day 5 post-castration. This would be possible if S100RVP was localized to the glandular epithelial cells of the prostate. To test this, mRNA in situ hybridization using a DIGlabelled S100RVP antisense riboprobe was carried out. As shown in fi gure 5, S100RVP mRNA was detected only in the glandular epithelial cells, which was lost on castration and restored with testosterone supplementation. In agreement with the data of northern blot, fl utamide treatment did not affect the epithelial expression of S100RVP. 
Effect of fl utamide on testosterone-mediated reversal of castration effects
Experiments discussed so far to study the effect of fl utamide involved analysis of gene expression following administration of fl utamide to intact animals. Testosterone supplementation to castrated rats not only causes reproliferation of prostate epithelial cells but also induces and suppresses androgen-induced and androgen-repressed genes respectively. The ability of fl utamide to block the testosterone-mediated reversal of castration effects on gene expression was also evaluated. For this purpose, animals were castrated and given intraperitoneal injections of fl utamide, testosterone propionate or both. Castrated control animals received the vehicle alone. The induction of prostatein C1 mRNA (a known androgen-induced gene) and PBPC1BS mRNA by testosterone supplementation to castrated animals was blocked by fl utamide. Flutamide also blocked the suppression of clusterin by testosterone. Interestingly, although as shown previously, fl utamide did not have any effect on A7 and S100RVP mRNA when injected into intact rats, it blocked the reappearance of A7 and S100RVP mRNAs by testosterone replacement (fi gure 6).
Discussion
Despite the widespread use of fl utamide for the treatment of prostate cancer, its effect on the physiology of the prostate has hardly been studied. A few independent research groups have studied the effect of fl utamide on gene expression in the RVP. These studies have revealed a differential effect of fl utamide on gene expression compared with castration Figure 5 . In situ hybridization analysis of the expression of S100RVP mRNA. a, day 5 sham-castrated; b, day 5 castrated; c, day 5 fl utamide-treated; d, testosterone-replaced. S, stroma; L, lumen (Russo et al 1994; Turner et al 2001; Leger et al 1988; Montalvo et al 2002) . Given the fact that fl utamide is an androgen receptor antagonist, the question as to why castration and fl utamide treatment should exert differential effects has not been addressed. The present study offers a possible explanation for the observed differential effects of castration and fl utamide treatment in the RVP. We have demonstrated differential expression patterns of transcripts identifi ed by DD-RT-PCR following castration and fl utamide treatment in the RVP. We have shown that the mRNA levels of clusterin, a known androgen-repressed gene, was increased by fl utamide treatment, albeit to a much lesser extent compared with castration. The steady-state level of PBPC1BS mRNA, a prostate-specifi c transcript, was decreased by both castration and fl utamide treatment. These fi ndings suggest that the effects of androgen on PBPC1BS and clusterin are mediated via the androgen receptor. On the other hand, while expression of A7 and S100RVP was severely decreased to levels beyond detection at day 5 post-castration, they were largely unaffected by fl utamide treatment. To our knowledge, this is the fi rst report on transcripts that are downregulated by castration but not by fl utamide treatment. Such differential effects of castration are inconsistent with the well-established idea of fl utamide as an androgen receptor antagonist.
Based on the published data on the effects of antiandrogens on androgen receptor function and localization, one may think of several possibilities for the differential effects of castration and fl utamide treatment. Antiandrogens have been shown to inhibit androgen receptor-responsive gene activation despite promoting androgen receptor nuclear import and DNA binding (Kemppainen et al 1992; Jenster et al 1993; Warriar et al 1993; Masiello et al 2002) . Interestingly, partial activation of the androgen receptor by androgen-receptor antagonists such as fl utamide and cyproterone acetate has also been demonstrated. Recently, Nguyen et al (2007) showed agonistic activity of fl utamide in neurons, which was androgen receptor dependent. Similar agonistic activities of fl utamide and other antiandrogens have been reported in several studies (Peterziel et al 1999; Evangelou et al 2000; Zhu et al 1999) . Both agonistic and antagonistic effects are also shown by selective oestrogen receptor modulators (Gustafsson 1998 ). Thus, it is possible that fl utamide assembles a transcriptionally active receptor on some while assembling a transcriptionally inactive receptor on other promoters, depending perhaps on the coactivators/corepressors that these complexes recruit. In a previous report, we showed that fl utamide increases the steady-state mRNA expression of pumilio 1 in the RVP while castration has no effect (Limaye et al 2007) . Possibly, the androgen receptor-independent actions of fl utamide may be the underlying cause of the observed differential effects of castration and fl utamide treatment. In this study, we have clearly demonstrated that fl utamide does not induce apoptosis of the RVP epithelium. We hypothesized that the differential effect of castration and fl utamide on the integrity of the RVP epithelium could be the underlying cause for the observed differential effects. In the following sections we discuss the supporting evidence for such a hypothesis.
The glandular epithelium comprises 85% of the cells in the RVP. Castration leads to apoptosis of the glandular epithelial cells causing severe depletion of the epithelial cell compartment (Kyprianou and Isaacs 1988; English et al 1989) . Hence, a gene represented only in the epithelial compartment would be observed as downregulated by castration merely due to its expression in the epithelium, irrespective of whether or not it is regulated by androgen. We observed a complete absence of TUNEL-positive nuclei in the ventral prostates of fl utamide-treated rats compared with those who underwent castration. Hence, the observed differential regulation of PBPC1BS, S100RVP and A7 could be a manifestation of the differences in integrity of the prostate epithelium following castration and fl utamide treatment. We proposed that S100RVP and A7 transcripts are epithelial-specifi c genes, which may not truly represent androgen-regulated genes in the RVP and whose expression depends upon the integrity of the prostate epithelium. Evidence supporting this is the clear epithelial localization of S100RVP detectable in control, testosterone-replaced and fl utamide-treated rats, but not in castrated rats. The other evidence for this is the kinetics of downregulation of the PBPC1BS and A7 mRNA transcripts following castration. Castration causes lowering of intraprostatic dihydrotestosterone (DHT) to levels below 5% of the control by 12-24 h post-castration (Kyprianou and Isaacs 1988) . However, apoptotic activity at day 1 post-castration is very low. In these conditions of very low prostatic DHT and low apoptotic activity at day 1 post-castration, PBPC1BS mRNA levels are reduced to 20% of the control, whereas A7 transcripts are reduced to only 80% of the control. A marked reduction in the A7 transcript level is observed only when peak apoptotic activity has set in at around day 3 postcastration. This suggests that the reduction of PBPC1BS mRNA is associated with the loss of testosterone, whereas the reduction of A7 transcripts is associated with the loss of epithelial cells. PBPC1BS, whose expression is also reduced by fl utamide treatment, may represent a gene that is truly androgen regulated.
Adult rats exposed to fl utamide in utero have been shown to exhibit severely compromised prostate growth and differentiation in a dose-dependent manner (ImperatoMcGinley et al 1992) , indicating the importance of the androgen receptor in epithelial proliferation during development. The phenomenon of stroma-directed epithelial proliferation recurs during regrowth of the prostatic epithelium following testosterone supplementation of castrated rats. Testosterone-induced increase in ventral prostate weight in castrated rats was shown to be blocked by fl utamide (Nellemann et al 2005) , indicating the ability of fl utamide to block reproliferation of the epithelium. In the present study, the effect of fl utamide on reversal by testosterone of the effects of castration was evaluated. Flutamide administered to intact rats did not have any effect on S100RVP and A7 transcript levels. However, the reappearance of these transcripts following testosterone supplementation of castrated animals was blocked by fl utamide treatment. This can be explained by the fact that fl utamide blocks reproliferation of the epithelium induced by testosterone replacement, and that A7 and S100RVP are epithelial-specifi c genes. This in turn supports the view that the expression of S100RVP and A7 in the RVP depends on the presence of intact epithelium and that an epithelialspecifi c gene observed as downregulated by castration at the whole prostate level need not necessarily be an androgenregulated gene.
The data presented in this paper clearly demonstrate that castration and fl utamide treatment have differential effects on gene expression. This study highlights the caveat in the widely used models of castration and testosterone replacement in identifi cation of androgen-regulated genes. We conclude that interpretation of genes as androgen regulated in the RVP based solely on the effects of castration and testosterone replacement could be misleading. This obviously has a lot of bearing with regard to the search for novel androgen-regulated genes as therapeutic targets or diagnostic markers for prostate carcinoma using the RVP model.
